STR-I-229-MTMX	
    			    			
                INSRMe011-A            
            
        General
Cell Line | 
					|
| hPSCreg name | INSRMe011-A | 
| Cite as: | INSRMe011-A (RRID:CVCL_C089) | 
| Alternative name(s) | 
									 
	STR-I-229-MTMX	 
							 | 
						
| Cell line type | Human embryonic stem cell (hESC) | 
| Similar lines | 
							 | 
					
| Last update | 30th August 2022 | 
| User feedback | |
Provider | 
					|
| Generator | 
							INSERM (INSRM)														    								 
    									Contact:
    									 
    																				Ontogeny of primordial germ cells  | 
					
| Derivation country | France | 
External Databases | 
						|
| Cellosaurus | CVCL_C089 | 
| Wikidata | Q54970623 | 
							    
							General Information | 
					|
| Publications | |
| * Is the cell line readily obtainable for third parties? | 
                                     Yes                                                                      | 
                            
Donor Information
General Donor Information | 
					|
| Sex | male | 
Phenotype and Disease related information (Donor) | 
					|
| Diseases | A disease was diagnosed.
																	 | 
					
| Disease associated phenotypes | 
								
  | 
						
Ethics
| Alternatives to consent are available? | Yes | 
| Alternatives to consent | |
| Alternative consent approval number | |
| How may genetic information associated with the cell line be accessed? | 
hESC Derivation
| Embryo stage | Blastula with ICM and Trophoblast | 
| PGD Embryo? | 
								 Yes 							 | 
						
| ZP removal technique | Enzymatic | 
Culture Conditions
| Surface coating | Gelatin | |||||||||
| Passage method | Mechanically | |||||||||
| CO2 Concentration | 5 % | |||||||||
| Medium | 
								Other medium:		 
			Base medium: Knockout-DMEM			 
				
				Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements 
				
  | 
						
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| DNMT3B | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| GABRB3 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| GDF3 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| POU5F1 (OCT-4) | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| SOX2 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| TDGF1 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| SSEA-1 | 
											 No 						                 | 
																                
						                
						                	 | 
						                ||||
| SSEA-4 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| TRA 1-81 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                
Differentiation Potency
Microbiology / Virus Screening | 
						|
| HIV 1 | Negative | 
| HIV 2 | Negative | 
| Hepatitis B | Negative | 
| Hepatitis C | Negative | 
Genotyping
Karyotyping (Cell Line) | 
					|
| Has the cell line karyotype been analysed? | 
								 Yes 								
																	
												46XY
											 
																				
																															
											Passage number: 6											 
																													 | 
						
Other Genotyping (Cell Line) | 
					|

Login to share your feedback, experiences or results with the research community.